Myriad Genetics, Inc. - SIC # 2835 - IN VITRO AND IN VIVO DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
MYGN Nasdaq 2835 https://myriad.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Myriad Genetics, Inc.

Raymond James Upgrades Natera & Myriad Genetics, While Downgrading This Stock - Jan 18th, 2023 6:11 pm
Myriad Genetics (MYGN) Ailed by Mounting Costs, FX Headwind - Jan 10th, 2023 2:26 pm
Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities - Jan 5th, 2023 12:05 pm
Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference - Jan 4th, 2023 1:00 pm
Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans - Dec 19th, 2022 9:05 pm
Further weakness as Myriad Genetics (NASDAQ:MYGN) drops 5.5% this week, taking five-year losses to 51% - Dec 19th, 2022 11:27 am
Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model - Dec 9th, 2022 12:15 am
Halozyme Therapeutics (HALO) Up 16.2% Since Last Earnings Report: Can It Continue? - Dec 8th, 2022 4:30 pm
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment - Nov 29th, 2022 9:05 pm
GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care - Nov 17th, 2022 12:05 pm
Myriad Genetics' (MYGN) UroSuite to Improve Tailored Treatment - Nov 14th, 2022 1:14 pm
Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting - Nov 14th, 2022 1:00 pm
Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information - Nov 10th, 2022 1:00 pm
Why Shares of Myriad Genetics Dropped 24% This Week - Nov 4th, 2022 1:51 am
New Study Published in JCO Precision Oncology Features Data Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries - Nov 3rd, 2022 10:00 pm
Myriad Genetics (MYGN) Q3 Earnings Miss, Gross Margin Falls - Nov 3rd, 2022 3:59 pm
Myriad Genetics Q3 Earnings Fall Short Of Expectations, Lowers Annual Outlook - Nov 1st, 2022 4:08 pm
Myriad Genetics (MYGN) Reports Q3 Loss, Lags Revenue Estimates - Nov 1st, 2022 2:25 pm
Myriad Genetics Expands Consumer Access to Genetic Testing with Acquisition of Gateway Genomics and Its Market-Leading SneakPeek® Early Gender DNA Test - Nov 1st, 2022 1:10 pm
Myriad Genetics Reports Third Quarter Financial Results - Nov 1st, 2022 1:05 pm